

ASX/Media Release

RESULTS OF ANNUAL GENERAL MEETING

SYDNEY, AUSTRALIA – 23 November 2022 – [Immutep Limited](#) (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company") advises that the results of its Annual General Meeting (AGM) are set out in the attached document in accordance with section 251AA(2) of the *Corporations Act 2001* (Cth) and Listing Rule 3.13.2.

Please be advised that all resolutions in the Company's 2022 Notice of Annual General Meeting were passed by the requisite majorities at today's AGM.

All resolutions were passed and decided by way of poll.

About Immutep

Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

Immutep's lead product candidate is eftilagimod alpha ("efti" or "IMP321"), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immutep's large pharmaceutical partners.

Further information can be found on the Company's website www.immutep.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (917) 679 9282; tim@lifesciadvisors.com

This announcement was authorised for release by Deanne Miller, COO & Company Secretary of Immutep Limited.

Immutep Limited
Annual General Meeting
Wednesday, 23 November 2022
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Direct votes (as at close of direct voting)			Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain	For	Against	Abstain*	Carried / Not Carried	No
1. Adoption of the Remuneration Report	Ordinary	262,232,408	10,133,859	2,395,662	2,017,939	311,259	195,837	0	265,157,347 96.25%	10,329,696 3.75%	2,017,939	Carried	N/A
2. Re-election of Director - Peter Meyers	Ordinary	286,269,672	2,545,097	2,139,326	1,728,468	429,074	78,022	0	289,056,090 99.10%	2,623,119 0.90%	1,728,468	Carried	N/A
3. Election of Director - Ms Lucy Turnbull	Ordinary	286,291,492	2,297,205	3,132,120	960,846	353,956	153,140	0	289,995,586 99.16%	2,450,345 0.84%	960,846	Carried	N/A
4. Election of Director - Dr Frederic Triebel	Ordinary	286,948,862	2,766,429	2,155,016	812,256	397,529	109,567	0	289,719,425 99.02%	2,875,996 0.98%	812,256	Carried	N/A
5. Approval of grant of performance rights to Mr Peter Meyers	Ordinary	272,191,098	17,522,542	2,060,275	908,648	311,013	186,083	0	274,700,404 93.94%	17,708,625 6.06%	988,648	Carried	N/A
6. Approval of grant of performance rights to Ms Lucy Turnbull	Ordinary	269,074,894	17,673,772	2,029,634	922,637	289,155	207,941	0	271,531,701 93.82%	17,881,713 6.18%	1,002,637	Carried	N/A
7. Approval of additional 10% placement capacity	Special	268,702,737	20,405,164	2,169,134	1,405,528	314,215	188,226	1,715	271,322,285 92.94%	20,595,209 7.06%	1,487,243	Carried	N/A

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.